162
Participants
Start Date
September 30, 2003
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
Venlafaxine
Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
CBT
CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
Progressive muscle relaxation therapy (PMR)
For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
Placebo medication
For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
Boston Medical Center, Boston
Center for Anxiety and Related Disorders, Boston
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Boston Medical Center
OTHER